| scholarly article | Q13442814 |
| P2093 | author name string | Farid Saad | |
| Louis J Gooren | |||
| P2860 | cites work | The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. | Q46850554 |
| Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy | Q46875718 | ||
| Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study | Q46881122 | ||
| Insulin sensitivity during combined androgen blockade for prostate cancer | Q46909972 | ||
| Testosterone replacement therapy and prostate cancer | Q46913725 | ||
| Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975 | Q46918551 | ||
| Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. | Q46947824 | ||
| A critical evaluation of simple methods for the estimation of free testosterone in serum. | Q49081910 | ||
| The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance | Q22305845 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency | Q28179470 | ||
| The decline of androgen levels in elderly men and its clinical and therapeutic implications | Q28251483 | ||
| Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy | Q28258997 | ||
| Testosterone deficiency, insulin resistance and the metabolic syndrome | Q28262608 | ||
| Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. | Q51035704 | ||
| Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. | Q51464753 | ||
| The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? | Q51490671 | ||
| Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. | Q52719647 | ||
| Rapidly shifting concepts regarding androgens and prostate cancer. | Q54968711 | ||
| Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. | Q55066612 | ||
| Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. | Q64916759 | ||
| Effects of testosterone supplementation in the aging male | Q67557606 | ||
| Adipose tissue distribution and function | Q67864882 | ||
| Longitudinal evaluation of serum androgen levels in men with and without prostate cancer | Q71700347 | ||
| Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism | Q71857797 | ||
| Development of prostate cancer after pituitary dysfunction: a report of 8 patients | Q73249755 | ||
| Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat | Q73318718 | ||
| Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants | Q73821554 | ||
| Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism | Q74146698 | ||
| The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men | Q79395871 | ||
| The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men | Q79407772 | ||
| Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy | Q79446008 | ||
| Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III) | Q79678541 | ||
| The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study | Q80129104 | ||
| Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations | Q81908673 | ||
| Sex differences in regional body fat distribution from pre- to postpuberty | Q84857350 | ||
| Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. | Q45267265 | ||
| Low serum testosterone and mortality in male veterans | Q45332648 | ||
| Regional obesity and risk of cardiovascular disease; the Framingham Study | Q45754192 | ||
| Lower testosterone levels predict incident stroke and transient ischemic attack in older men. | Q45926620 | ||
| Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. | Q45939568 | ||
| Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. | Q45995127 | ||
| Testosterone and obesity in men under the age of 40 years | Q46100643 | ||
| Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer | Q46150022 | ||
| Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes | Q46355385 | ||
| Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations | Q46541677 | ||
| Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. | Q46570705 | ||
| Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. | Q46595277 | ||
| Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study | Q46757585 | ||
| Prevalence of overweight and obesity in the United States, 1999-2004 | Q28305811 | ||
| The metabolic syndrome | Q29616309 | ||
| Alterations in growth and body composition during puberty: III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release | Q30472079 | ||
| Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis | Q33222142 | ||
| The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity | Q33550783 | ||
| The metabolic syndrome--a neuroendocrine disorder? | Q33964740 | ||
| Endogenous sex hormones in men aged 40-80 years | Q33974189 | ||
| Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only | Q34003029 | ||
| Androgen replacement therapy in the aging male--a critical evaluation | Q34277156 | ||
| Hormones and prostate cancer: what's next? | Q34393202 | ||
| Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors | Q34457503 | ||
| Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis | Q34502187 | ||
| Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency | Q34531591 | ||
| Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q34545044 | ||
| Effect of puberty on body composition | Q34912405 | ||
| The role of testosterone in the metabolic syndrome: a review | Q34981185 | ||
| The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process | Q34982639 | ||
| Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat | Q35006662 | ||
| Testosterone therapy and prostate carcinoma | Q35009920 | ||
| Prevalence of hypogonadism in males aged at least 45 years: the HIM study | Q35037892 | ||
| Risks of testosterone-replacement therapy and recommendations for monitoring | Q35641798 | ||
| Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk | Q35794460 | ||
| Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. | Q35862931 | ||
| Direct effects of sex steroid hormones on adipose tissues and obesity | Q35905509 | ||
| Testosterone therapy in the ageing male: what about the prostate? | Q35947307 | ||
| Testosterone treatment for the aging man: the controversy | Q35947451 | ||
| Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit | Q35967464 | ||
| The development of prostate cancer despite late onset androgen deficiency. | Q36275532 | ||
| Low serum testosterone and mortality in older men. | Q36360750 | ||
| Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline | Q36486899 | ||
| The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms | Q36537386 | ||
| Elevated body mass index and mortality risk in the elderly | Q36703092 | ||
| Body composition, metabolic syndrome and testosterone in ageing men. | Q36842367 | ||
| Testosterone concentration in young patients with diabetes | Q36906249 | ||
| Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups | Q36938377 | ||
| Sexual dimorphism of body composition | Q36944272 | ||
| Androgen deficiency, diabetes, and the metabolic syndrome in men. | Q36973087 | ||
| Androgens and body fat distribution | Q36975178 | ||
| Role of body fat distribution and the metabolic complications of obesity | Q36979749 | ||
| Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study | Q37105445 | ||
| Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes | Q37139412 | ||
| Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations | Q37310024 | ||
| Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania | Q37317410 | ||
| Testosterone in obesity, metabolic syndrome and type 2 diabetes | Q37326209 | ||
| Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy | Q37372781 | ||
| The dark side of testosterone deficiency: III. Cardiovascular disease | Q37431142 | ||
| Testosterone and prostate cancer: revisiting old paradigms | Q37450000 | ||
| Obesity and testicular function | Q37525109 | ||
| The role of testosterone in type 2 diabetes and metabolic syndrome in men. | Q37686143 | ||
| Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial | Q38402163 | ||
| The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study | Q38487266 | ||
| Testosterone replacement in prostate cancer survivors with hypogonadal symptoms | Q39295915 | ||
| The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men | Q39513420 | ||
| Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials | Q39738952 | ||
| The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation | Q39919146 | ||
| Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study | Q40760488 | ||
| Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels | Q42478739 | ||
| Prostate cancer after exogenous testosterone treatment for impotence | Q42550086 | ||
| Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome | Q43278811 | ||
| Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study | Q43297274 | ||
| Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. | Q43705618 | ||
| Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study | Q43843236 | ||
| Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes | Q43959465 | ||
| Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. | Q44470244 | ||
| Aging, androgens, and the metabolic syndrome in a longitudinal study of aging | Q44525492 | ||
| A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern | Q44585247 | ||
| Sex hormones, inflammation and the metabolic syndrome: a population-based study | Q44670623 | ||
| Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. | Q44685104 | ||
| Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer | Q44836371 | ||
| Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. | Q44865591 | ||
| Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial | Q45071179 | ||
| Waist circumference and testosterone levels in community dwelling men. The Tromsø study | Q45087781 | ||
| Effects of androgen therapy on adipose tissue and metabolism in older men. | Q45096562 | ||
| Testosterone replacement therapy after primary treatment for prostate cancer | Q45219185 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | obesity | Q12174 |
| metabolic syndrome | Q657193 | ||
| testosterone | Q1318776 | ||
| type 2 diabetes | Q3025883 | ||
| testosterone | Q27863114 | ||
| P304 | page(s) | 683-685 | |
| P577 | publication date | 2010-08-10 | |
| P1433 | published in | Journal of Obesity | Q26842383 |
| P1476 | title | The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. | |
| P478 | volume | 2011 |
| Q43244910 | A 47,X,+t(X;X)(p22.3;p22.3)del(X)(p11.23q11.2),Y Klinefelter variant with morbid obesity |
| Q41573277 | A Comparative Study of Australian and New Zealand Male and Female Nurses' Health: A Sex Comparison and Gender Analysis. |
| Q64260365 | A Short Study Exploring the Effect of the Glycaemic Index of the Diet on Energy intake and Salivary Steroid Hormones |
| Q36370472 | A cross-sectional study of the association of age, race and ethnicity, and body mass index with sex steroid hormone marker profiles among men in the National Health and Nutrition Examination Survey (NHANES III) |
| Q35573457 | Acute testosterone deprivation reduces insulin sensitivity in men |
| Q36697884 | An overview of the contribution of fatness and fitness factors, and the role of exercise, in the formation of health status for individuals who are overweight |
| Q37851063 | Androgen deficiency in heart failure |
| Q57828021 | Benefits and Consequences of Testosterone Replacement Therapy: A Review |
| Q35682481 | Cell-Based High-Throughput Screening for Aromatase Inhibitors in the Tox21 10K Library |
| Q35810628 | Connecting the Lines between Hypogonadism and Atherosclerosis |
| Q35624509 | Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism |
| Q24288837 | Diet, exercise or diet with exercise: comparing the effectiveness of treatment options for weight-loss and changes in fitness for adults (18-65 years old) who are overfat, or obese; systematic review and meta-analysis |
| Q38071006 | Do we need anti-obesity drugs? |
| Q34063853 | Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). |
| Q59813297 | Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study |
| Q89161029 | Endocrine treatment of aging transgender people |
| Q35994260 | Hormonal determinants of the severity of andropausal and depressive symptoms in middle-aged and elderly men with prediabetes |
| Q40698744 | Is testosterone deficiency a possible risk factor for priapism associated with sickle-cell disease? |
| Q34516774 | Molecular sex differences in human serum |
| Q37502104 | Multiple hormonal dysregulation as determinant of low physical performance and mobility in older persons. |
| Q35750773 | Nature of fatty acids in high fat diets differentially delineates obesity-linked metabolic syndrome components in male and female C57BL/6J mice |
| Q49971559 | Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. |
| Q30403762 | Obese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus |
| Q21256713 | Randomized control trial to evaluate the effects of acute testosterone administration in men on muscle mass, strength, and physical function following ACL reconstructive surgery: rationale, design, methods |
| Q91768365 | Relationship of transcriptional markers to Leydig cell number in the mouse testis |
| Q39432023 | Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report |
| Q37306092 | The effect of obesity and components of metabolic syndrome on urinary and sexual functions in Saudi men |
| Q48685313 | The inter-relational effect of metabolic syndrome and sexual dysfunction on hypogonadism in type II diabetic men. |
| Q48072729 | The practical management of testosterone deficiency in men. |
| Q36796228 | The role of androgens and estrogens on healthy aging and longevity |
| Q38057355 | The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism |
| Q34108216 | The role of the urologist in the prevention and early detection of cardiovascular disease |
| Q36932044 | What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? |
Search more.